Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial.

PubWeight™: 1.08‹?› | Rank: Top 10%

🔗 View Article (PMID 11755921)

Published in Atherosclerosis on January 01, 2002

Authors

James D Otvos1, Irina Shalaurova, David S Freedman, Robert S Rosenson

Author Affiliations

1: Department of Biochemistry, North Carolina State University, Raleigh, NC, USA.

Articles citing this

LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol (2007) 2.21

Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. J Am Coll Cardiol (2016) 1.49

Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant (2011) 1.18

Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care (2009) 1.14

Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. Lipids Health Dis (2009) 0.91

Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther (2013) 0.87

Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. J Am Heart Assoc (2013) 0.87

Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation (2015) 0.83

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy. J Am Heart Assoc (2015) 0.81

Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis. Adv Healthc Mater (2015) 0.78

Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. Nat Clin Pract Cardiovasc Med (2008) 0.75

Articles by these authors

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation (2006) 4.25

Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93

Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. Am J Clin Nutr (2009) 3.90

High adiposity and high body mass index-for-age in US children and adolescents overall and by race-ethnic group. Am J Clin Nutr (2010) 3.22

Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis (2007) 2.84

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67

Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One (2010) 2.59

Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol (2002) 2.38

Statins: panacea for sepsis? Lancet Infect Dis (2006) 2.32

An assessment of statin safety by muscle experts. Am J Cardiol (2006) 2.16

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol (2011) 2.16

Unexplained decline in the prevalence of anemia among US children and women between 1988-1994 and 1999-2002. Am J Clin Nutr (2008) 2.16

Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol (2002) 2.15

Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem (2004) 2.05

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care (2010) 1.86

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation (2010) 1.69

Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes (2010) 1.52

High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50

Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs (2013) 1.43

Smoothed percentage body fat percentiles for U.S. children and adolescents, 1999-2004. Natl Health Stat Report (2011) 1.31

The pediatric obesity epidemic continues unabated in Bogalusa, Louisiana. Pediatrics (2010) 1.27

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27

Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol (2013) 1.24

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2008) 1.21

Do skinfold measurements provide additional information to body mass index in the assessment of body fatness among children and adolescents? Pediatrics (2007) 1.18

Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am (2004) 1.17

Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol (2010) 1.09

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens (2011) 1.09

Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. Ethn Dis (2007) 1.06

Limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease. J Am Coll Cardiol (2013) 1.06

Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets. Postgrad Med (2005) 1.05

Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol (2010) 1.04

Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation (2004) 1.00

Ethnic differences in subcutaneous adiposity and waist girth in children and adolescents. Obesity (Silver Spring) (2009) 0.98

Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment? Cardiovasc Drugs Ther (2010) 0.96

Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. J Cardiometab Syndr (2007) 0.96

Floating light-activated microelectrical stimulators tested in the rat spinal cord. J Neural Eng (2011) 0.94

Cardiovascular disease prevention and care in Latino and Hispanic subjects. Endocr Pract (2007) 0.93

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med (2010) 0.92

Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis (2008) 0.91

Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther (2012) 0.88

Use of density-equalizing cartograms to visualize trends and disparities in state-specific prevalence of obesity: 1996-2006. Am J Public Health (2008) 0.87

Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther (2009) 0.87

Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther (2004) 0.87

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc Imaging (2014) 0.86

Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis (2007) 0.86

An interferometric reflectance imaging sensor for point of care viral diagnostics. IEEE Trans Biomed Eng (2013) 0.85

Variations of whole blood viscosity using Rheolog-a new scanning capillary viscometer. Clin Chim Acta (2003) 0.85

Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol (2007) 0.84

Endothelial shear stress and blood viscosity in peripheral arterial disease. Curr Atheroscler Rep (2014) 0.84

Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol (2012) 0.84

Incidences of obesity and extreme obesity among US adults: findings from the 2009 Behavioral Risk Factor Surveillance System. Popul Health Metr (2011) 0.83

Emerging drugs for hyperlipidemia. Expert Opin Emerg Drugs (2010) 0.81

Physicians' interpretation of "class effects": a need for thoughtful re-evaluation. J Am Coll Cardiol (2002) 0.81

Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther (2010) 0.81

Importance of blood rheology in the pathophysiology of atherothrombosis. Cardiovasc Drugs Ther (2012) 0.81

Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol (Oxf) (2002) 0.81

Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. Diabetes Care (2013) 0.81

Statin therapy: new therapy for cardiac microvascular dysfunction. Eur Heart J (2003) 0.81

Role of HDL in those with diabetes. Curr Cardiol Rep (2014) 0.80

Hyperinsulinemia and homeostasis model assessment of insulin resistance as predictors of hypertension: a 5-year follow-up study of Korean sample. Am J Hypertens (2011) 0.79

Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diab Vasc Dis Res (2012) 0.79

Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy. Clin Hemorheol Microcirc (2010) 0.79

Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther (2011) 0.79

Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol (2014) 0.78

A mass-tagging approach for enhanced sensitivity of dynamic cytokine detection using a label-free biosensor. Langmuir (2013) 0.78

Field of confusion: future prospects for fibrate therapy in cardiovascular disease. Curr Atheroscler Rep (2006) 0.78

Trends in Obesity Among Participants Aged 2-4 Years in the Special Supplemental Nutrition Program for Women, Infants, and Children - United States, 2000-2014. MMWR Morb Mortal Wkly Rep (2016) 0.78

Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther (2012) 0.77

Elevated coronary whole blood viscosity in acute coronary syndrome patients. Clin Hemorheol Microcirc (2013) 0.77

Shear rate specific blood viscosity and shear stress of carotid artery duplex ultrasonography in patients with lacunar infarction. BMC Neurol (2013) 0.77

Chronic tissue response to untethered microelectrode implants in the rat brain and spinal cord. J Neural Eng (2015) 0.77

Recombinant high-density lipoprotein formulations. Curr Atheroscler Rep (2011) 0.77

Effects of hydration on blood rheology. Clin Hemorheol Microcirc (2003) 0.77

Vascular biomarkers in the metabolic syndrome. Expert Rev Mol Diagn (2009) 0.76

Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol (2009) 0.76

Determination of body size measures and blood pressure levels among children. J Pediatr (Rio J) (2013) 0.76

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol (2012) 0.76

Secular trends in pediatric BMI. Am J Clin Nutr (2012) 0.75

Off-target toxicity: risks associated with adrenal corticoid activation in ILLUMINATE. Curr Atheroscler Rep (2008) 0.75

SPARCL: statin therapy for stroke patients is not crystal clear. Curr Atheroscler Rep (2007) 0.75

Reply: Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution. J Am Coll Cardiol (2015) 0.75

Acute-phase reactants and coronary heart disease. Semin Vasc Med (2002) 0.75

2013 ACC/AHA Guideline: a guideline for the population - without evidence from the population. Cardiovasc Drugs Ther (2014) 0.75

Preanalytical sources of measurement error: the conundrum of the homocysteine hypothesis. Atherosclerosis (2006) 0.75

Targeting dyslipidemia--the key to CHD risk reduction in the diabetic population? Diabetes Res Clin Pract (2005) 0.75

Role of statin therapy in stroke prevention. J Am Soc Hypertens (2010) 0.75

Reply: Statin Intolerance and Risk for Recurrent Myocardial Infarction, Coronary Heart Disease Events, and All-Cause Mortality. J Am Coll Cardiol (2017) 0.75

High-throughput label-free detection of DNA hybridization and mismatch discrimination using interferometric reflectance imaging sensor. Methods Mol Biol (2013) 0.75

Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield. Curr Atheroscler Rep (2013) 0.75

Role of HDL in those with diabetes. Curr Cardiol Rep (2014) 0.75

Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. J Am Coll Cardiol (2017) 0.75

Comparison of two whole blood viscometers: implications for cardiovascular and thrombosis research. Thromb Haemost (2004) 0.75

An analog VLSI implementation of the inner hair cell and auditory nerve using a dual AGC model. IEEE Trans Biomed Circuits Syst (2014) 0.75